Abstract:Objective To determine the population pharmacokinetics of valproic acid(VPA) and identify the factors that explained PK variability in Chinese epileptic children.Methods 390 steady-state serum concentration samples were collected totally.The plasma samples for VPA concentration were analyzed using automated fluorescence polarization method(FPIA) with monoclonal antibodies.In total,321 patients aged 1.8(0.1-13.6) years and weighted 11.5(2.6-84) kg with 390 trough concentrations were extracted.Total body weight,VPA daily dose,gender and comedication with clonazepam,topiramate,carbamazepine,phenobarbital and oxcarbazepine were considered as covariates.A decrease of OFV(from basic model to covariate model) by more than 6.63 was considered to be statistically significant(P0.01,df=1).An increase of OFV from the full model of at least 10.83(P0.001,df = 1) was used as the chosen criterion for retaining the covariate in the model.Pharmacokinetic modeling was performed using NONMEM program(version 6,level 1.1) complied with G77 Fortran.A one-compartment pharmacokinetic model with first-order absorption and elimination(subroutine ADVAN2 and TRANS2) was used to describe the concentration-time data.The first-order conditional estimation method with η-e interaction(FOCE-I) was used throughout the model-building procedure.Various statistical models describing the random residual variability were considered.The reliability and stability of the population pharmacokinetic model developed was further assessed by a nonparametric bootstrap procedure.During this process,each patient was randomly sampled with replacement from the original data set to form new data set containing the same number of patients as the original data set.Results The final model for VPA apparent clearance(CL/F),including age(years),CLO comedication and liver enzyme inducer(carbamazepine or phenobarbital) covariates with a significant influence on this parameter,was as follows: CL/F=0.223·(Age/1.8)0.353·1.22CLO·1.36LEI,V=13.0·(Total body weight/11.5) where CLO was 1 when co-medicated with clonazepam preparation,otherwise CLO was 0;LEI was 1 when co-medicated with carbamazepine or phenobarbital preparation.The typical values for CL/F and apparent volume of distribution(V/F) were 0.223 L·h-1 and 13.0 L,respectively.Interindividual variability(coefficient of variation) for CL/F was 34.3% for final model and 51.5% for basic model;The residual unexplained variability was 25.6 %.In a single attempt of 200 bootstrap analysis,6(3.0%) runs terminated due to rounding errors and were excluded in the analysis.The parameter(except V/F) estimates from nonparametric bootstrap procedure were comparable and within 5% of the estimates from NONMEM.Conclusions A population pharmacokinetic model was proposed to estimate the individual CL/F for paediatric patients receiving VPA in terms of patient′s age,and concomitant clonazepam,carbamazepine or phenobarbital,in order to establish a prior dosage regimens.

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis

Developing pharmacokinetics–pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients

Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen

A randomized controlled trial of initial Valproic acid dosage in epileptic children

Population Pharmacokinetics of Valproic Acid in Epileptic Children: Effects of Clinical and Genetic Factors.

Population Pharmacokinetics of Valproate in Chinese Children with Epilepsy.

Factors associated with subtherapeutic levels of valproic acid in hospitalized patients with epilepsy: A retrospective cohort study

Association of Valproic Acid and Its Main Metabolites Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring

Progress in Population Pharmacokinetic of Valproic Acid

Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained‐release tablets

Establishment of Population Phamacokinetic Model of Valproic Acid in Chinese Epileptic Children

A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation

Setting up population pharmacokinetics/pharmacodynamics model of VPA in children with epilepsy by NONMEM software

Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients with Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy

Population Pharmacokinetics of Valproate in Children with Epilepsy by NONMEM

Simultaneous Determination of Valproic Acid and 2-Propyl-4-pentenoic Acid for the Prediction of Clinical Adverse Effects in Chinese Patients with Epilepsy

Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy

Population Pharmacokinetics and Exposure-Safety of Lipophilic Conjugates Prodrug DP-VPA in Healthy Chinese Subjects for Dose Regime Exploring

Establishment of Population Pharmacokinetic Models with Valproic Acid in Different Age Groups of Chinese Epileptic Children

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy

Determination of Valproic Acid and Its Six Metabolites in Human Serum Using LC-MS/MS and Application to Interaction with Carbapenems in Epileptic Patients